Alnylam Pharmaceuticals Inc
XETRA:DUL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alnylam Pharmaceuticals Inc
XETRA:DUL
|
US |
|
Stora Enso Oyj
OTC:SEOAY
|
FI |
|
Esperion Therapeutics Inc
LSE:0IIM
|
US |
Wall St Price Targets
DUL Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for DUL is 395.71 EUR with a low forecast of 208.3 EUR and a high forecast of 519.34 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is DUL's stock price target?
Price Target
395.71
EUR
According to Wall Street analysts, the average 1-year price target for DUL is 395.71 EUR with a low forecast of 208.3 EUR and a high forecast of 519.34 EUR.
What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
18%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 18%.
What is the Gross Profit forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
19%
The compound annual growth rate for Gross Profit over the next 8 years is 19%.
What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
37%
The compound annual growth rate for Operating Income over the next 8 years is 37%.
What is the Pre-Tax Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
93%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 93%.
What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
40%
The compound annual growth rate for Net Income over the next 8 years is 40%.
